Revenue
No reported data
Vera Therapeutics, Inc. (VERA)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $215.3M | $126.2M | $78.2M | $69.0M | $22.5M | $45.2M |
| Operating expenses | $315.5M | $167.2M | $102.0M | $90.9M | $34.4M | $52.2M |
| Operating income | −$315.5M | −$167.2M | −$102.0M | −$90.9M | −$34.4M | −$52.2M |
| EBITDAderived | −$315.0M | −$167.1M | −$102.0M | — | −$34.2M | −$52.0M |
| Net income | −$299.6M | −$152.1M | −$96.0M | −$89.1M | −$32.6M | −$53.4M |
| Basic EPSper diluted share | -$4.66 | -$2.75 | -$2.25 | -$3.35 | -$2.43 | -$166.93 |
| Diluted EPSper diluted share | -$4.66 | -$2.75 | -$2.25 | -$3.35 | -$2.43 | -$166.93 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 23, 2026Form 4 · 10b5-1 | Fordyce MarshallPRESIDENT AND CEO | SellClass A Common Stock | 88 | $38.43 | $3.4K | 198.2K |
| Jun 23, 2026Form 4 · 10b5-1 | Fordyce MarshallPRESIDENT AND CEO | SellClass A Common Stock | 18.4K | $37.93 | $698.4K | 198.3K |
| May 12, 2026Form 4 · 10b5-1 | Fordyce MarshallPRESIDENT AND CEO | SellClass A Common Stock | 4.3K | $37.09 | $158.8K | 216.7K |
| May 12, 2026Form 4 · 10b5-1 | Fordyce MarshallPRESIDENT AND CEO | SellClass A Common Stock | 14.2K | $36.64 | $521.0K | 221.0K |
| Apr 14, 2026Form 4 · 10b5-1 | Fordyce MarshallPRESIDENT AND CEO | SellClass A Common Stock | 900 | $45.51 | $41.0K | 235.2K |